Genetic testing for familial cancer: The French national report (year 2003)

Community Genetics

Volumn 11, Issue 1, 2008, Pages 63-67

  Eisinger, François ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

BRCA; Germline mutation; Health policy; Health services; Hereditary cancer; Neoplastic syndromes; Program evaluation

Indexed keywords

ARTICLE; BREAST CANCER; CANCER GENETICS; CANCER RESEARCH; CONTROLLED STUDY; CORRELATION ANALYSIS; FAMILIAL CANCER; GENE MUTATION; HEALTH CARE FACILITY; HUMAN; MAJOR CLINICAL STUDY; MISMATCH REPAIR; PRIORITY JOURNAL; TUMOR GENE;

BREAST NEOPLASMS; DNA MUTATIONAL ANALYSIS; FAMILY HEALTH; FEMALE; FRANCE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HEALTH SURVEYS; HUMANS; MUTATION; NEOPLASMS; OVARIAN NEOPLASMS;

EID: 38349055057     PISSN: 14222795     EISSN: None     Source Type: Journal    
DOI: 10.1159/000111640     Document Type: Article

References (15)

1. Eisinger F, Guagliardo V, Julian-Reynier C, Moatti J: Dépistage des cancers; in Guilbert P, Baudier F, Gautier A (eds): Baromètres santé2000. Paris, CFES, 2001, pp 329-355.
2. Remontet L, Estève J, Bouvier AM, Grosclaude P, Launoy G, Menegoz F, Exbrayat C, Tretare B, Carli PM, Guizard AV, Troussard X, Bercelli P, Colonna M, Halna JM, Hedelin G, Mace-Lesec'h J, Peng J, Buemi A, Velten M, Jougla E, Arveux P, Le Bodic L, Michel E, Sauvage M, Schvartz C, Faivre J: Cancer incidence and mortality in France over the period 1978-2000). Rev Epidemiol SantéPublique, 2003;51(1 Pt 1):3-30.
3. Cannell E: The French Cancer Plan: an update. Lancet Oncol 2005;6:738.
4. Syngal S, Weeks JC, Schrag D, Garber JE, Kuntz KM: Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. Ann Intern Med 1998;129:787-796.
5. Jarvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomaki P, De La Chapelle A, Mecklin JP: Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000;118:829-834.
6. Schrag D, Kuntz KM, Garber JE, Weeks JC: Decision analysis - effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997;336:1465-1471.
7. Hartmann LC, Sellers TA, Schaid DJ, Frank TS, Soderberg CL, Sitta DL, Frost MH, Grant CS, Donohue JH, Woods JE, McDonnell SK, Vockley CW, Deffenbaugh A, Couch FJ, Jenkins RB: Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001;93:1633-1637.
8. Domchek SM, Friebel TM, Neuhausen SL, Wagner T, Evans G, Isaacs C, Garber JE, Daly MB, Eeles R, Matloff E, Tomlinson GE, Van't Veer L, Lynch HT, Olopade OI, Weber BL, Rebbeck TR: Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 2006;7:223-229.
9. Eisinger F, Bressac B, Castaigne D, Cottu PH, Lansac J, Lefranc JP, Lesur A, Nogues C, Pierret J, Puy-Pernias S, Sobol H, Tardivon A, Tristant H, Villet R: Identification and management of hereditary predisposition to cancer of the breast and the ovary (update 2004) (in French). Bull Cancer 2004;91:219-237.
10. Olschwang S, Bonaiti C, Feingold J, Frebourg T, Grandjouan S, Lasset C, Laurent-Puig P, Lecuru F, Millat B, Sobol H, Thomas G, Eisinger F: Identification and management of HNPCC syndrome (hereditary non polyposis colon cancer), hereditary predisposition to colorectal and endometrial adenocarcinomas (in French). Bull Cancer 2004;91:303-315.
11. Sevilla C, Bourret P, Nogues C, Moatti JP, Sobol H, Julian-Reynier C: The supply of breast/ovarian cancer genetic susceptibility tests in France (in French). Med Sci (Paris) 2004;20:788-792.
12. Garber JE, Offit K: Hereditary cancer predisposition syndromes. J Clin Oncol 2005;23:276-292.
13. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, adopted on February 20, 1996. J Clin Oncol 1996;14:1730-1736, discussion 1737-1740.
14. Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, Critchfield GC: Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002;20:1480-1490.
15. Russell AM, Zhang J, Luz J, Hutter P, Chappuis PO, Berthod CR, Maillet P, Mueller H, Heinimann K: Prevalence of MYH germline mutations in Swiss APC mutation-negative polyposis patients. Int J Cancer 2006;118:1937-1940.